# Immunic, Inc. (IMUX)

> Source: Nexqual · https://nexqual.com/IMUX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Immunic, Inc. (IMUX), nexqual.com/IMUX" · informational, not investment advice.

**Price:** USD 7.1 (+6.61% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 6.66 · day 6.59–7.14 · 52w 5.06–17.43 · market cap $96.9M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 43.09 (range 22–85).
- Total return with dividends: 1Y -13.0% vs S&P 500 +18.1%; 5Y -91.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-13, EPS estimate USD -0.96, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 43.09 (low 22, high 85).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Wedbush | Reiterated | Outperform | $45 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Buy | $22 |
| 2026-08-17 | Wedbush | Initiated | Outperform | $45 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -13.0% | -91.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -13.0% | -39.3% |
| Volatility (annualized) | 82.1% | 117.6% |
| Max drawdown | -60.6% (Aug 2026→Oct 2026) | -95.9% (Feb 2022→Dec 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/IMUX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt